Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
2 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
24 Oct 23
8-K
Biostax Corp Announces the Passing of Esteemed Director, Henry Louis Salomonsky
14 Sep 23
8-K
Departure of Directors or Certain Officers
13 Sep 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Entry into a Material Definitive Agreement
20 Apr 23
10-K
2022 FY
Annual report
10 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
DEF 14C
Information statement
27 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
6 Mar 23
PRER14C
Preliminary revised information
28 Feb 23
PRER14C
Preliminary revised information
12 Jan 23
8-K
Departure of Directors or Certain Officers
3 Jan 23
PRE 14C
Preliminary information
16 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Entry into a Material Definitive Agreement
9 Nov 22
8-K
Entry into a Material Definitive Agreement
12 Oct 22
8-K
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
27 Sep 22
D
$5M in debt
31 Aug 22
10-Q
2022 Q2
Quarterly report
24 Aug 22
NT 10-Q
Notice of late quarterly filing
9 Aug 22
8-K
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
4 Aug 22
D
$400K in Convertible Debt, sold $400K, 1 investor
2 Aug 22
8-K
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
22 Jul 22
8-K
Entry into a Material Definitive Agreement
7 Jul 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
18 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
8-K
Other Events
2 Jun 21
10-Q
2021 Q1
Quarterly report
24 May 21
NT 10-Q
Notice of late quarterly filing
18 May 21
10-K
2020 FY
Annual report
15 Apr 21
Latest ownership filings
4
Glen A Farmer
22 Feb 23
SC 13D
Salomonsky Henry Louis
15 Dec 22
3
Initial statement of insider ownership
15 Dec 22
3
Henry Louis Salomonsky
15 Dec 22
3
Glen A Farmer
15 Dec 22
3
Kelly O'Brien Wilson
15 Dec 22
3
FAMILY TRUST DTD ROGOFF
7 Jun 21
SC 13D
Griffin Noreen
7 Jun 21
3
Joel Yanowitz
7 Jun 21
3
George Sasko
7 Jun 21
3
Deane Rhodes
7 Jun 21
3
Initial statement of insider ownership
7 Jun 21
3
Paul Puskadi
7 Jun 21
3
Initial statement of insider ownership
7 Jun 21
3
Initial statement of insider ownership
7 Jun 21
3
Chris Dunk
7 Jun 21
3
ROBERT JACKMAN DAILEY
7 Jun 21
3
James Norman Curley
7 Jun 21
3
Alan CUNNINGHAM
7 Jun 21
3
Roger Dale BOZARTH
7 Jun 21
4
Noreen Griffin
4 Jun 21
SC 13G/A
Ahmetaj Erjon
26 Jun 20
SC 13G/A
Iliad Research & Trading, L.P.
19 May 20
SC 13G
Immune Therapeutics, Inc.
10 Dec 19
SC 13G/A
Immune Therapeutics, Inc.
16 May 19
SC 13G
Immune Therapeutics, Inc.
15 May 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
Richard Gostanian
2 Apr 18
5
ROBERT JACKMAN DAILEY
30 Mar 18